View : 1 Download: 0
Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)
- Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)
- Kim, Yeon-Joo; Park, Won; Ha, Boram; Park, Boram; Joo, Jungnam; Kim, Tae Hyun; Park, In Hae; Lee, Keun Seok; Lee, Eun Sook; Shin, Kyung Hwan; Kim, Haeyoung; Il Yu, Jeong; Choi, Doo Ho; Huh, Seung Jae; Wee, Chan Woo; Kim, Kyubo; Park, Kyung Ran; Kim, Yong Bae; Ahn, Sung Ja; Lee, Jong Hoon; Kim, Jin Hee; Chun, Mison; Lee, Hyung-Sik; Kim, Jung Soo; Cha, Jihye
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- CANCER RESEARCH AND TREATMENT
- 1598-2998; 2005-9256
- vol. 49, no. 4, pp. 927 - 936
- Breast neoplasms; Radiotherapy; Taxane; Recurrence; Disease-free survival; Survival
- KOREAN CANCER ASSOCIATION
- SCIE; SCOPUS; KCI
- Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [-]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane-based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.